{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T04:03:59Z","timestamp":1769573039160,"version":"3.49.0"},"reference-count":36,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Vernal keratoconjunctivitis is a persistent allergic ocular disease predominantly mediated by the T-helper 2 lymphocyte-associated immune response. The standard therapeutic approaches for vernal keratoconjunctivitis include topical corticosteroids and immunosuppressive eye drops. However, managing vernal keratoconjunctivitis with only topical treatments becomes challenging during seasonally exacerbated periods. Systemic treatments such as oral corticosteroids or cyclosporine may be alternative options. Recently, dupilumab\u2019s efficacy in refractory vernal keratoconjunctivitis treatment has been documented. Here, we report a case of refractory vernal keratoconjunctivitis coexisting with atopic dermatitis that rapidly improved after upadacitinib administration. An 18-year-old Japanese woman presented with atopic dermatitis, vernal keratoconjunctivitis, and hay fever. In winter, the patient experienced widespread erythema and escalated itching, leading to significant discomfort and insomnia. Owing to the difficulty in maintaining her current regimen, upadacitinib (15 mg), a Janus kinase inhibitor was initiated. After upadacitinib administration, the treatment-resistant vernal keratoconjunctivitis and erythema improved. Upadacitinib is beneficial in severe cases of atopic dermatitis. Consequently, in our case, upadacitinib may offer therapeutic benefits for refractory vernal conjunctivitis by improving the T-helper 1\/2 type immune response, autoimmunity, and oxidative stress. To our knowledge, this is the first report suggesting the potential utility of upadacitinib in managing severe vernal conjunctivitis.<\/jats:p>","DOI":"10.3390\/diagnostics14121272","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T04:48:12Z","timestamp":1718599692000},"page":"1272","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Case of Refractory Vernal Keratoconjunctivitis Showing Improvement after the Administration of Upadacitinib for the Treatment of Atopic Dermatitis"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4832-1899","authenticated-orcid":false,"given":"Yoshihito","family":"Mima","sequence":"first","affiliation":[{"name":"Department of Dermatology, Tokyo Metropolitan Police Hospital, Tokyo 164-8541, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eri","family":"Tsutsumi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, International University of Health and Welfare Hospital, Tochigi 324-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Ohtsuka","sequence":"additional","affiliation":[{"name":"Department of Dermatology, International University of Health and Welfare Hospital, Tochigi 329-2763, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ippei","family":"Ebato","sequence":"additional","affiliation":[{"name":"Department of Dermatology, International University of Health and Welfare Hospital, Tochigi 329-2763, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiro","family":"Nakata","sequence":"additional","affiliation":[{"name":"Department of Dermatology, International University of Health and Welfare Hospital, Tochigi 329-2763, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Kubota","sequence":"additional","affiliation":[{"name":"Department of Dermatology, International University of Health and Welfare Hospital, Tochigi 329-2763, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7649-0806","authenticated-orcid":false,"given":"Yuta","family":"Norimatsu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, International University of Health and Welfare Narita Hospital, Chiba 286-0124, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/ACI.0b013e3282efb726","article-title":"Clinical Grading of Vernal Keratoconjunctivitis","volume":"7","author":"Bonini","year":"2007","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s12016-023-08970-4","article-title":"Vernal Keratoconjunctivitis: A Systematic Review","volume":"65","author":"Bruschi","year":"2023","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/ACI.0000000000000672","article-title":"Adult Vernal Keratoconjunctivitis","volume":"20","author":"Bonini","year":"2020","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1755-3768.2008.01347.x","article-title":"Vernal Keratoconjunctivitis: A Major Review","volume":"87","author":"Kumar","year":"2009","journal-title":"Acta Ophthalmol."},{"key":"ref_5","unstructured":"Brindisi, G., Cinicola, B., Anania, C., De Castro, G., Nebbioso, M., Miraglia Del Giudice, M., Licari, A., Caffarelli, C., De Filippo, M., and Cardinale, F. (2021). Vernal Keratoconjunctivitis: State of Art and Update on Treatment. Acta Biomed., 92."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Hehar, N.K., and Chigbu, D.I. (2024). Vernal Keratoconjunctivitis: Immunopathological Insights and Therapeutic Applications of Immunomodulators. Life, 14.","DOI":"10.3390\/life14030361"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0161-6420(00)00092-0","article-title":"Vernal Keratoconjunctivitis Revisited","volume":"107","author":"Bonini","year":"2000","journal-title":"Ophthalmology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.alit.2017.10.002","article-title":"Barrier Dysfunction in the Skin Allergy","volume":"67","author":"Egawa","year":"2018","journal-title":"Allergol. Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cytogfr.2018.07.001","article-title":"Autophagy and Proinflammatory Cytokines: Interactions and Clinical Implications","volume":"43","author":"Ge","year":"2018","journal-title":"Cytokine Growth Factor. Rev."},{"key":"ref_10","first-page":"1419","article-title":"Vernal Keratoconjunctivitis: Atopy and Autoimmunity","volume":"17","author":"Zicari","year":"2013","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/pai.13382","article-title":"Is Oxidative Stress Involved in Vernal Keratoconjunctivitis? Results from a Pilot Study in Children","volume":"31","author":"Zicari","year":"2020","journal-title":"Pediatr. Allergy Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1111\/all.13786","article-title":"Management of Ocular Allergy","volume":"74","author":"Leonardi","year":"2019","journal-title":"Allergy"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/aos.14858","article-title":"Comparative Efficacy of Medical Treatments for Vernal Keratoconjunctivitis in Children and Young Adults: A Systematic Review with Network Meta-analyses","volume":"100","author":"Rasmussen","year":"2022","journal-title":"Acta Ophthalmol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1177\/11206721211022153","article-title":"Vernal Keratoconjunctivitis: An Update","volume":"31","author":"Ghiglioni","year":"2021","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"472","DOI":"10.2165\/00003088-199324060-00004","article-title":"Cyclosporin Clinical Pharmacokinetics","volume":"24","author":"Fahr","year":"1993","journal-title":"Clin. Pharmacokinet."},{"key":"ref_16","first-page":"137","article-title":"Mechanism of Action of the New Immunosuppressants: Cyclosporin A, FK 506 and Rapamycin","volume":"13","author":"Rondeau","year":"1992","journal-title":"Nephrologie"},{"key":"ref_17","unstructured":"Kaur, K., and Gurnani, B. (2024). Vernal Keratoconjunctivitis. StatPearls [Internet], StatPearls Publishing."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/j.jfo.2018.04.009","article-title":"Oral Cyclosporine for Severe Vernal Keratoconjunctivitis in Children","volume":"42","year":"2019","journal-title":"J. Fr. Ophtalmol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4103\/0301-4738.179727","article-title":"Systematic Approach to Managing Vernal Keratoconjunctivitis in Clinical Practice: Severity Grading System and a Treatment Algorithm","volume":"64","author":"Gokhale","year":"2016","journal-title":"Indian J. Ophthalmol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s11882-013-0345-0","article-title":"Use of Cyclosporine A and Tacrolimus in Treatment of Vernal Keratoconjunctivitis","volume":"13","author":"Vichyanond","year":"2013","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/pai.12737","article-title":"Vernal Keratoconjunctivitis Treated with Omalizumab: A Case Series","volume":"28","author":"Occasi","year":"2017","journal-title":"Pediatr. Allergy Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1111\/ceo.14142","article-title":"Successful Treatment and Prevention of the Recurrence of Refractory Vernal Keratoconjunctivitis with Dupilumab","volume":"50","author":"Tsui","year":"2022","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0014-4835(02)00248-8","article-title":"IL-4-Induced Cell Proliferation and Production of Extracellular Matrix Proteins in Human Conjunctival Fibroblasts","volume":"76","author":"Fujitsu","year":"2003","journal-title":"Exp. Eye Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jfma.2012.07.017","article-title":"Surgical Management and Immunohistochemical Study of Corneal Plaques in Vernal Keratoconjunctivitis","volume":"112","author":"Lin","year":"2013","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1111\/jdv.17824","article-title":"A Rare Case of Vernal Keratoconjunctivitis in a Patient with Atopic Dermatitis Treated with Tralokinumab","volume":"36","author":"Lai","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jaad.2021.07.002","article-title":"Janus Kinase Inhibitors in Dermatology: Part I. A Comprehensive Review","volume":"86","author":"Chapman","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20140712","article-title":"The Molecular Regulation of Janus Kinase (JAK) Activation","volume":"462","author":"Babon","year":"2014","journal-title":"Biochem. J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1126\/science.7973659","article-title":"Functional Activation of Jak1 and Jak3 by Selective Association with IL-2 Receptor Subunits","volume":"266","author":"Miyazaki","year":"1994","journal-title":"Science"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Furue, M. (2020). Regulation of Skin Barrier Function via Competition between AHR Axis versus IL-13\/IL-4\u2013JAK\u2013STAT6\/STAT3 Axis: Pathogenic and Therapeutic Implications in Atopic Dermatitis. J. Clin. Med., 9.","DOI":"10.3390\/jcm9113741"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting Key Proximal Drivers of Type 2 Inflammation in Disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_31","first-page":"3858032","article-title":"IL-33\/IL-31 Axis: A Potential Inflammatory Pathway","volume":"2018","author":"Casciaro","year":"2018","journal-title":"Mediat. Inflamm."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/76923","article-title":"Cloning of a Receptor Subunit Required for Signaling by Thymic Stromal Lymphopoietin","volume":"1","author":"Pandey","year":"2000","journal-title":"Nat. Immunol."},{"key":"ref_33","first-page":"e51196","article-title":"Transepidermal Water Loss and T-Helper 2 (Th2)-Associated Inflammatory Markers in Two Pediatric Patients during the First Four Weeks of Treatment with the Oral Janus Kinase Inhibitor Upadacitinib","volume":"15","author":"Horimukai","year":"2023","journal-title":"Cureus"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e13688","DOI":"10.1111\/cts.13688","article-title":"Upadacitinib: Mechanism of Action, Clinical, and Translational Science","volume":"17","author":"Mohamed","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK\u2013STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.3389\/fimmu.2019.02814","article-title":"JAK Inhibitors and Oxidative Stress Control","volume":"10","author":"Charras","year":"2019","journal-title":"Front. Immunol."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/14\/12\/1272\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:59:45Z","timestamp":1760108385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/14\/12\/1272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,17]]},"references-count":36,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["diagnostics14121272"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics14121272","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,17]]}}}